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 ABSTRACT 
Introduction Skeletal muscle atrophy, weakness, mitochondrial loss and dysfunction are charac-
teristics of chronic obstructive pulmonary disease (COPD). It remains unclear whether muscle 
dysfunction is localized to the lower limbs, because findings are inconsistent in the few studies 
where upper and lower limb muscle performance properties were compared within an individual. 
This study determined whether muscle oxidative capacity is low in both upper and lower limbs of 
COPD patients compared with controls. Methods Oxidative capacity of the forearm and medial 
gastrocnemius were measured using near-infrared spectroscopy to determine the muscle O2 con-
sumption recovery rate constant (k, min-1) in 20 COPD (GOLD 2/3/4, n=7/7/6) and 20 smokers 
with normal spirometry (CON). Muscle k is linearly proportional to oxidative capacity. Steps/day 
and vector magnitude units (VMU)/min were assessed using triaxial accelerometry. Differences 
between group and limb were assessed by 2-way ANOVA. Results There was a significant main 
effect of group (F=11.2, ηp2=0.13, P=0.001): k was lower in both upper and lower limb muscles in 
COPD (1.01±0.17, 1.05±0.24 min-1) compared with CON (1.29±0.49, 1.54±0.60 min-1). There was 
no effect on k of limb (F=1.8, ηp2=0.02, P=0.18) or group x limb interaction (P=0.35). VMU/min 
was significantly lower in COPD (-38%; P=0.042). Steps/day did not differ between COPD 
(4738±3194) and CON (6372±2107; P=0.286), although the difference exceeded a clinically im-
portant threshold (>600-1100 steps/day). Conclusion Compared with CON, muscle oxidative ca-
pacity was lower in COPD in both upper (-20%) and lower (-30%) limbs. These data suggest that 
mitochondrial loss in COPD is not isolated to locomotor muscles. 
KEY WORDS: Mitochondria; Near-infrared spectroscopy; Exercise intolerance; Oxygen con-
sumption; Inactivity; Dyspnea 
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 INTRODUCTION 
Skeletal muscle dysfunction is one of the most important extra-pulmonary manifestations 
impairing quality-of-life of patients with chronic obstructive pulmonary disease (COPD). Loss of 
muscle mass, strength and power, loss of type I (oxidative) muscle fibers, capillary rarefaction, 
mitochondrial loss and mitochondrial dysfunction have each been identified and appear to progress 
with COPD severity(1-6) 
 
 Investigations of muscle dysfunction in COPD typically focus on locomotor muscles, es-
pecially of the quadriceps, because of their key role in ambulation, autonomy(7) and quality of life. 
However, prevalence and progression of disease-associated adaptations in upper limbs or trunk 
muscles are less well characterized. Muscle dysfunction isolated to the lower limbs within an in-
dividual implies causal mechanisms proximal to reduced locomotion, while dysfunction of both 
upper and lower limbs suggests a wider range of systemic mechanisms contributing to muscular 
impairments, e.g. chronic inflammation, oxidative stress, hypoxemia, nutrition, cigarette smoke or 
other circulating variables(2, 4, 8-10). 
 
Few studies, largely limited to functional performance measures (strength, endurance), 
have compared upper and lower limb muscles within individual COPD patients; and their findings 
are variable. Bernard et al.(11) found greater loss of strength in the lower than the upper limb of 
COPD patients compared with age-matched non-smoking controls. Weakness and low isometric 
strength was found in both upper and lower limbs of COPD patients compared with age-matched 
healthy controls(12-14), but biceps brachii endurance was better preserved than in the quadriceps 
in a large study of COPD patients(13). These findings contrast with smaller cohorts studied by 
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 Miranda et al.(7) and Vilaró et al.(15), who showed that endurance and fatigability(7), and isomet-
ric strength(15), were more impaired in upper than lower limbs of COPD patients. Currently, there 
are no muscle biopsy studies comparing properties of arm and leg muscles within the same indi-
viduals. Therefore, the systemic or local cellular adaptations, that underlie strength or endurance 
deficits in COPD patients, are not known. 
 
To address this, we determined upper (medial forearm) and lower (gastrocnemius) limb 
muscle oxidative capacity in moderate to very-severe COPD patients compared with age-matched 
smokers with normal spirometry (CON). We used near-infrared spectroscopy (NIRS(1)) to deter-
mine non-invasively the recovery rate constant (k) of muscle oxygen consumption (mV̇O2(16)) iso-
lated from influences of circulatory or pulmonary function. mV̇O2 recovery k is directly propor-
tional to muscle oxidative capacity measured in single muscle fibers (r2=0.77(17)). NIRS-based 
oxidative capacity assessment has been validated against magnetic resonance spectroscopy and 
biopsy in skeletal muscle(18, 19). Based on previous reports of upper and lower limb muscle en-
durance in COPD patients(13), we hypothesized that, compared with CON, COPD patients would 
have a greater deficit in muscle oxidative capacity in the gastrocnemius than in the forearm. 
 
MATERIALS AND METHODS 
Participants 
A group of current or former smokers with at least 10 pack-years smoking history were 
enrolled: twenty moderate to very-severe COPD patients (GOLD stage 2-4) and twenty age- and 
sex-matched participants with normal spirometry (CON) (Table 1). Current or former smokers 
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 without COPD were selected as the appropriate comparator group for COPD patients with a smok-
ing history. This attempts to isolate the effects of COPD on muscle oxidative capacity and control 
for the potential influence of smoking history. It is recognized that the control group in this study 
do not necessarily represent a “normal” or “healthy” condition. All participants were 45 to 90 years 
old. Controls had pre-bronchodilator FEV1/FVC ≥0.70 and FEV1 ≥80%predicted. COPD patients 
(post-bronchodilator FEV1/FVC <0.70 and FEV1 <80%predicted) were in a stable state, with no 
exacerbation within previous 4-weeks. Exclusion criteria were: presence of significant disease 
other than COPD (a significant disease was defined as a disease which may: (i) put the patient at 
risk by participation; (ii) influence the results of the study, such as ischemic heart disease, chronic 
musculoskeletal or renal disease; or (iii) limit the patient’s ability comply with the protocol); active 
participation in pulmonary rehabilitation or participation in the past 18 months; pregnancy in 
women. Participants were informed about study procedures and risks and gave written informed 
consent. The study was approved by the Human Subjects Committee of The Lundquist Institute 
for Biomedical Innovation at Harbor-UCLA Medical Center (20403-01). 
 
Measurements 
Each participant visited the laboratory once, during which NIRS muscle and spirometry 
tests were performed. Participants completed symptom (COPD Assessment Test, CAT; modified 
Medical Research Council Dyspnea scale, mMRC) and health-related quality of life (St. George’s 
Respiratory Questionnaire, SGRQ; 36-Items Short Form Health Survey, SF-36) questionnaires. 
The SGRQ and SF-36 physical activity-related domains were used to evaluate daily physical ac-
tivity (PA). In addition, PA was objectively assessed in all COPD patients and 6 CON using 7-day 
triaxial accelerometry (Dynaport MoveMonitor, McRoberts BV, NL). 
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 NIRS muscle oxidative capacity test 
 The non-dominant forearm and medial gastrocnemius muscles were assessed using contin-
uous-wave, spatially-resolved spectroscopy NIRS (PortaMon, Artinis BV, NL). NIRS measures 
relative concentration of deoxygenated (HHb+Mb) and oxygenated (HbO2+MbO2) hemoglobin 
and myoglobin within the muscle up to ~1.5 cm under the probe. From these measurements, rela-
tive changes in total hemoglobin and myoglobin (THb = HHb+Mb+HbO2+MbO2) were calculated. 
Tissue saturation index (TSI, an index of tissue oxygen saturation) was calculated from these meas-
urements. 
 
 With the participant supine on an exam bed, the belly of the calf and forearm muscles were 
identified. Palpation during a series of brief isometric muscle contractions was used to optimize 
placement of the plastic-wrapped NIRS probe(1) longitudinally over a highly activated region of 
the medial forearm and medial gastrocnemius. The NIRS probe was then secured in position using 
an elastic bandage. A rapid-inflation pressure-cuff (SC12D, Hokanson, USA) was placed on the 
upper arm or proximal thigh on the same limb as the NIRS probe and attached to an electronically-
controlled rapid cuff-inflator (E20, Hokanson, USA). The participant was asked to relax and min-
imize upper limb (UL) or lower limb (LL) movement, except when instructed. Participants were 
familiarized with rapid cuff-inflation and to the brief muscle contractions required in the protocol. 
Arterial occlusion pressure was determined for both limbs from a tolerated cuff-pressure within 
the range of 175-275 mmHg (mean: UL = 221±24, and LL = 218±31 mmHg) that resulted in a rise 
in HHb+Mb, a fall in HbO2+MbO2 and stable THb signal over 15-20 s. Repeated dynamic muscle 
contractions were made at ~1 Hz by squeezing a foam tennis ball (forearm) or a plantar-flexion/re-
laxation against a light resistance (lower leg) (hereafter referred to as muscle contractions). 
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  Initially, participants lay at rest for 2-3 min to establish a stable baseline TSI. After this, 
~10-15 s of light muscle contractions were performed to increase mV̇O2 and the limb subjected to 
arterial occlusion until a stable minimum TSI was reached or for 5 min (whichever occurred first). 
Cuff pressure was then released and the subsequent reactive reoxygenation monitored until resting 
baseline was reestablished (typically ~8 min for UL, and ~3.5 min for LL). This was used to de-
termine an individualized muscle saturation physiological range (Figure 1). Finally, two muscle 
oxidative capacity assessments were performed for each limb. Each consisted of: 1) ~10-15 s mus-
cle contractions to increase mV̇O2 and desaturate the muscle to ~50% of the physiological 
range(1); 2) a series of intermittent arterial occlusions (5 occlusions for 5 s, 10 for 10 s, each 
separated by 5-20 s recovery) (Figure 1). Each of the assessments lasted ~6 min and were separated 
by ~2 min of rest. Participants were provided ~15 min between UL and LL testing. UL was always 
tested first. At the end of the procedure the skinfold at the NIRS site was measured to estimate 
adipose tissue thickness (ATT, mm; Table 1) (Lange Skinfold Caliper, BetaTechnology Inc., Santa 
Cruz, CA). 
 
For each intermittent arterial occlusion during oxidative capacity tests, the linear rate of 
decline in TSI (desaturation in %.s-1) was determined and a point value for relative mV̇O2 reported. 
Because the rate of tissue deoxygenation during arterial occlusion is inversely proportional to 
mV̇O2, its value is reported as positive (%.s-1; Figure 2). The primary study outcome was the ex-
ponential mV̇O2 recovery rate constant (k, min-1), which was estimated using non-linear least-
squares regression (Figure 2) (OriginPro v8.6, OriginLab Co., Northampton, USA(1)). This pro-
tocol has strong test-retest reliability in smokers with and without COPD (ICC ≥0.88)(1). 
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 Pulse oximetry 
Arterial oxygen saturation was estimated during resting phase at the beginning of testing 
using fingertip pulse oximetry (SpO2; Rad-5 Pulse Oximeter MasimoSET®, Masimo Co., Irvine, 
CA). 
 
Spirometry 
Participants inhaled two puffs of metered dose albuterol sulfate ~15 min before spirometric 
testing. Spirometry was performed in accordance with American Thoracic Society guidelines using 
a dual-beam Doppler ultrasound-based spirometer (EasyOne Pro, Ndd Medical, Zürich, Switzer-
land). Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were meas-
ured from the greatest FEV1 and FVC from up to eight maximum expiratory maneuvers, where 
the greatest two measurements were within 150 mL. 
 
Physical activity by triaxial accelerometry 
 All COPD patients and 6 CON underwent 7 days of PA monitoring using triaxial acceler-
ometry (Dynaport MoveMonitor, McRoberts BV, NL). Each participant was instructed in the cor-
rect positioning of the monitor in small of the back, and to adjust the elastic waistband to ensure 
the device was in contact with the body and comfortable. Participants were asked to wear the PA 
monitor for as long as possible during each 24-hour period, and to remove it only for bathing and 
swimming. The PA monitor was worn from the end of the study visit until 7 full days had elapsed. 
Data were processed using the manufacturer’s protocols. 
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 Daily PA measurements were accepted as valid if they met the criteria that the monitor was 
worn for at least 8 hours/day during waking hours (20) and for at least 5 days/week (not necessarily 
consecutive, without distinction between weekdays and weekends). Compliance with these condi-
tions was ~94%. PA is reported as the mean number of steps per day (total accumulated during 
each 24 hour period), and as the mean count of vector magnitude units per minute (VMU/min) 
during “daytime” hours between 8 AM and 11 PM. VMU is the vectorial sum of movements meas-
ured at 100Hz from acceleration in the three orthogonal planes (sagittal, frontal, transversal) meas-
ured over a one-minute time period. The acceleration signal is converted to a digital representation 
and processed to obtain an “activity count”, i.e. VMU (for additional details see e.g.(21)). 
 
Statistics 
Coefficient of variation (CV) and intraclass correlation coefficient (ICC) assessed within-
subject test-retest reproducibility. Two-way ANOVA was used to identify k differences between 
group (COPD and CON) and limb (UL and LL). Associations were investigated by regression 
(Pearson). Significant differences were accepted at P ≤ 0.05. Results are presented as mean ± SD, 
unless otherwise specified. 
 
RESULTS 
Participant characteristics 
 One COPD patient could not tolerate UL arterial occlusion, and therefore the patient and 
the corresponding age- and sex-matched control were excluded from further analysis. Results are 
reported from 19 COPD and 19 CON. As intended, groups were matched by age and body char-
acteristics (Table 1). Four COPD patients required nasal cannula O2 during the visit (at 2 L.min-1). 
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 Symptoms, physical activity and quality of life 
COPD patients had significantly greater CAT and mMRC scores than CON, confirming 
greater dyspnea in patients (Table 2). Significantly greater (worse) SGRQ total and subscale scores, 
and lesser SF-36 physical and general health component aggregate scores, confirmed lower quality 
of life in COPD than CON (Table 2). COPD reported lower scores than CON in physical function-
ing and role-physical scales of SF-36 (P<0.001), suggesting reduced capacity for performing daily 
and physical activities. 
 
Triaxial accelerometry wearing compliance was met on 6 days (≥15 hours/day) on average 
in both in COPD and CON (Table 2B), except for one GOLD 1 patient who withdrew on day 2. 
Therefore, results are presented for 6 individuals in each group. The characteristics of sub-group 
of 6 controls who undertook accelerometry assessment were: 5 males, 1 female; 56±26 years; 
1.70±0.60 m; 66.0±32.5 kg; FEV1 2.44±1.13 L; FVC 3.20±1.53 L. VMU/min was significantly 
lower (P=0.024) in COPD than CON. Although steps/day were not significantly different between 
COPD and CON (P=0.286, Table 2B), the mean difference exceeded the clinically important dif-
ference established for COPD (600-1100 steps/day(22)). 
 
Upper and lower limb muscle oxidative capacity 
 Resting muscle TSI and adipose tissue thickness of the upper and lower extremities were 
not significantly different between COPD and CON (Table 3). There was no significant difference 
between the first and second k measurements within individuals for either limb; therefore, the 
average of the two repeated k values are reported. Test-retest reliability was high for upper and  
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 lower limb k values in both groups (COPD UL: CV=3.8%, ICC=0.96; LL: CV=4.6%, ICC=0.96; 
and CON UL: CV=5.4%, ICC=0.98; LL: CV=4.5%, ICC=0.98). 
 
 There was main effect of group on k (F=11.2, ηp2=0.13, P=0.001) but not of limb (F=1.8, 
ηp2=0.02, P=0.18). There was no group-by-limb interaction (P=0.35). Compared with CON, 
COPD patients had significantly lower k in upper (~20%) and lower (~30%) limbs (Table 3, Figure 
3). There was no significant association between measures of physical activity (VMU/min; 
steps/day) and k in the lower limbs of COPD (r2=0.06-0.13; P>0.05) or CON (r2=0.17-0.25; 
P>0.05). 
  
DISCUSSION 
This is the first study to determine skeletal muscle oxidative capacity in both upper and 
lower extremities of current or former smokers with or without COPD. Given the large volume of 
muscle biopsy data showing low muscle oxidative capacity in moderate to severe COPD patients, 
we hypothesized that lower limb muscle oxidative capacity would be more severely impaired, 
compared with matched smoker controls, than the upper limb. Contrary to our hypothesis, there 
was no interaction between group and limb for muscle k. We found COPD patients had substan-
tially lower muscle oxidative capacity (20-30%) in both locomotor and forearm skeletal muscles 
compared with smokers without pulmonary obstruction (Table 3, Figure 3). This deficit in muscle 
oxidative capacity in COPD was accompanied by a lower VMU/min and clinically important (but 
not statistically significant) reduction in steps/day in COPD. However, there were only weak as-
sociations between k and physical activity (VMU/min or steps/day) in the lower limb (r2=0.06-
0.25). Together, the findings of low oxidative capacity in upper limb and low oxidative capacity 
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 that was only weakly associated with activity in the lower limb, in COPD patients and controls 
well matched for smoking history, age and sex, suggest a systemic deficit in muscle oxidative 
capacity in COPD patients that is not well explained by a low volume and/or intensity of physical 
activity alone. 
  
Upper and lower limb muscle oxidative capacity in COPD 
The severity of the muscle oxidative capacity deficit in the lower limbs of COPD patients 
(~20-30%) is similar to reports from biopsy studies of the quadriceps (~10-50%)(23). There is only 
one previous report of muscle biopsy analysis from the upper limb (deltoid) of 10 COPD patients, 
and this showed a trend (P=0.07) for lower citrate synthase activity compared with controls(24). 
The ~20-30% lower muscle oxidative capacity in COPD would likely translate into similar reduc-
tion in oxidative ATP synthesis in COPD(5, 25-27), but could be impacted further should mito-
chondrial uncoupling be increased (e.g., to mitigate oxidative stress). 
 
In humans, the medial gastrocnemius has a greater expression of type I fibers than the 
forearm muscles(28, 29), where muscle fiber characteristics favor acute strength and precision of 
movement over muscle endurance. Because of this, we anticipated that, overall, the lower limb 
muscles would have a greater oxidative capacity than the upper limb. However, we did not identify 
a statistical effect of limb, potentially because the study was underpowered for this comparison. 
The study was powered on the basis of anticipated differences of the primary outcome (k) between 
COPD and controls, and achieved a power (1-β) of 0.89 to detect this large effect (Cohen’s d=1.07) 
(G*power 3.1). While there was a trend towards an effect of limb in controls (lower limb k = 
1.54±0.60 min-1 vs. upper limb k = 1.29±0.49 min-1), the effect size was small (d=0.46) and the 
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 power for this comparison was low (1-β=0.28), suggesting the potential for type II error (false 
negative interpretation). We estimate that 150 participants would be needed to determine with a 
power of 1-β=0.8 whether muscle oxidative capacity in middle-age smoker controls differed be-
tween upper and lower limbs. 
 
However, we were surprised that muscle oxidative capacity was very similar in upper and 
lower limb muscles in COPD, and was lower in both muscles than even the upper limb muscles in 
controls. This highlights the severity of the profound loss of mitochondrial function in the ambu-
latory muscles of COPD patients, given that forearm muscles typically contain far more type II 
muscle fibers and are far more fatigable. It also suggests a systemic mechanism may contribute 
strongly to whole-body mitochondrial loss in COPD(30). 
 
Support for this concept can be found in the study by Rabinovich et al.(31), who reported 
that reduced mitochondrial density and function (coupling of oxidative phosphorylation) was 
strongly related with PaO2 and early lactate release during exercise. Circulating cigarette smoke 
constituents (e.g. reactive aldehydes), oxidative stress and/or systemic inflammation and cytokine 
expression may impair mitochondrial dynamics or biogenesis(4, 32), or impair the neuromuscular 
junction(33), interrupting calcineurin signaling and other calcium-sensitive cellular mediators, 
each contributing to oxidative capacity loss in muscle. While cigarette smoke constituents have 
been implicated in directly inhibiting oxidative phosphorylation (e.g. by inhibition of cytochrome 
c oxidase), studies to investigate this in humans have been inconsistent in their findings(32). In a 
previous NIRS study of 39 smokers without COPD, we were unable to identify a direct effect of 
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 current smoking on muscle oxidative capacity(34). However, the degree to which the loss of skel-
etal muscle oxidative capacity is pathological or a consequence of mitochondrial functional phe-
notype adaptations induced by muscle fiber switch and physical inactivity is still unclear(4, 35). 
 
Several studies have reported a preservation of type I fiber number, strength(24, 36) or 
endurance(13) in upper limb muscles of COPD patients, suggesting that muscle structural altera-
tions are not homogeneously distributed among different muscle groups in COPD(4, 23). One in-
terpretation of this is that reduced ambulation and consequent muscular deconditioning is a pri-
mary driver of the low oxidative muscle phenotype in the legs of COPD patients, while upper limb 
muscles may be better protected through engagement in activities of daily living. Although our 
physical activity data predominantly reflect activity of the lower limb muscles, overall our data do 
not support this proposal. Rather they suggest a systemic loss of the oxidative muscle phenotype 
in COPD(4, 23, 30, 35, 37). 
 
Other structural changes, particularly loss of muscle mass, which is a strong predictor of 
mortality in COPD(4), has been implicated in reduced endurance (directly related to oxidative 
capacity) and strength in COPD patients. Franssen et al.(13) compared quadriceps and biceps bra-
chii muscle strength and endurance in COPD patients with and without muscle mass depletion and 
found a significant reduction in strength only in the lower limbs of those who had lost fat free mass 
(FFM). However, the authors reported that this difference disappeared after correcting for 
FFM(13), suggesting that the loss of FFM contributes to muscle weakness in COPD but other 
factors should be considered to explain endurance impairments in COPD. Although we did not 
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 assess muscle mass or FFM in our study, we sought stable COPD patients without recent exacer-
bations or uncontrolled weight loss in the previous 6 months, and BMI was not different from 
controls on average (24±4 kg/m2). Although BMI is a crude index, 6 COPD patients in our study 
had BMI <21 kg/m2 (range 18.2 to 20.3 kg/m2; GOLD 2/3/4 n=2/3/1), suggested as the lower limit 
of normal for chronic disease patients(4). Nevertheless, the mean k in this sub-group (UL = 
0.91±0.12 min-1; LL = 1.05±0.24 min-1) was not significantly different from the COPD group as 
a whole, suggesting that low oxidative capacity is not a characteristic solely of underweight or 
undermuscled subjects. Our findings appear relevant to a general COPD population rather than 
those with overt weight loss or muscle weakness. 
 
The levels of physical activity we found in our COPD patients were similar to those re-
ported in literature (38-40), while our smoker-controls were less active than reports for similar 
middle-aged individuals (e.g. ~9,000 steps/day; c.f. Table 2). The groups also differed in pulmo-
nary function (by design), dyspnea and self-reported physical functioning and quality-of-life (Ta-
ble 2) and one objective measure of activity (VMU/min), but were otherwise not different in smok-
ing history, age, or sex. While we also found no significant difference in steps/day between COPD 
and CON (P=0.286), the mean difference (1634 steps/day; an effect size of d=0.60) exceeded es-
tablished clinical importance (600-1100 steps/day) that corresponds to a reduced risk of hospitali-
zation(22) and morbidity. This suggests that physical activity is lower in COPD than controls in 
our study by a clinically relevant magnitude, and it is likely that the study is underpowered to 
detect a statistically significant difference between COPD and controls in the secondary outcome 
of steps/day (1-β=0.44). Nevertheless, we found no association between objectively measured 
physical activity and k, suggesting that factors in addition to – or, perhaps, other than – physical 
 
AC
CE
PT
ED
 activity are responsible for low oxidative capacity in muscles of COPD patients. Further study of 
a larger cohort is warranted to investigate this suggestion. 
 
Study limitations 
We used non-invasive assessment of muscle oxidative capacity to allow two muscle sites 
to be investigated. This assessment is reliable and has been validated against gold standard meth-
ods (biopsy and magnetic resonance spectroscopy). Nevertheless, this assessment is indirect and 
does not provide a detailed picture of intramyocyte signaling processes that contribute to mito-
chondrial loss. We did not assess muscle mass, FFM, muscle endurance or strength in this study, 
to provide insight into how muscle oxidative capacity loss associates with muscle quantity or per-
formance. This study was also relatively small, enrolling no more than seven subjects per each 
GOLD 2 to 4 category. Therefore, the study was not sufficiently powered to identify an effect of 
disease severity on upper and lower limb muscle oxidative capacity. The two NIRS-investigated 
sites are representative of skeletal muscles involved in daily activities (i.e. grasping or carrying for 
the forearm and locomotion for the gastrocnemius); the selection of the muscle sites is limited by 
the NIRS-based technique, which requires the ability to implement repeated arterial occlusions(41). 
Therefore, a wider systemic assessment of respiratory abdominal or vertebral muscles is not pos-
sible with this method. We used accelerometry to provide an objective evaluation of the daily 
physical activity, which predominantly represents activity of the lower limbs, therefore upper limb 
activity remains unmeasured in our study. 
 
 
 
 
AC
CE
PT
ED
 Clinical implications and future perspectives 
 Low oxidative capacity in the locomotor muscle is associated with exercise intolerance and 
therefore may contribute to inactivity, poor quality-of-life and represents a strong therapeutic tar-
get(4, 23). It is known that locomotor muscles respond well to endurance exercise training by 
increasing oxidative capacity, even in COPD patients(4, 13). However, if muscle mitochondrial 
loss is systemic in COPD - and perhaps even not limited to the muscle tissues - then exercise 
training would be expected to ameliorate this deficit only in the muscles engaged by training, but 
not in a wider range of locations or tissues. Ameliorating systemic mitochondrial dysfunction may 
need additional, possibly pharmaceutical, therapies as an adjunct to exercise training in COPD 
patients. Systemic mitochondrial loss could contribute to immune system or liver dysfunction and 
cardiovascular disease, which are each prevalent in COPD patients. As such, the NIRS we used 
for this study may represent a relatively simple and non-invasive method to investigate the severity 
of systemic mitochondrial dysfunction and response to therapy. Future studies with a larger cohort 
are needed to identify whether severity of the pulmonary and/or physical activity impairments are 
associated with oxidative capacity loss of the upper and lower limbs in COPD. Comprehensive 
evaluation of exercise capacity and isolated muscle structure and function are needed to identify 
the clinical correlates and physiological mediators underlying these observations. 
 
CONCLUSION 
We found that muscle oxidative capacity was low in both upper (forearm) and lower (me-
dial gastrocnemius) limb muscles of moderate to very-severe COPD patients compared with sex 
and age-matched smokers with normal spirometry. Low oxidative capacity was not limited to the 
lower limbs or to those with COPD. Low muscle oxidative capacity in COPD may contribute to 
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 the greater respiratory symptoms and reduced muscle endurance and quality of life in COPD pa-
tients. These data imply that low oxidative capacity in leg muscles of COPD patients may not 
solely relate to reduced ambulation and deconditioning, but that systemic factors e.g. inflammation 
or oxidative stress, are likely strong mediators loss of mitochondrial oxidative phenotype. 
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 FIGURE LEGENDS 
 
Figure 1. Changes in tissue saturation index (TSI) during the NIRS muscle test. Three protocol 
phases are shown. The grey shading indicates muscle contractions, always preceded by a resting 
(i.e. baseline) phase. Data are from the medial gastrocnemius muscle of a control individual. 
 
Figure 2. Representative COPD and control (CON) responses for the muscle oxidative capacity 
assessments. Muscle oxygen consumption (mV̇O2) recovery following brief contractions is shown, 
with a mono-exponential fit (dashed line), for the upper (medial forearm muscle, left) and lower 
(medial gastrocnemius, right) limb. COPD, chronic obstructive pulmonary disease; UL, upper 
limb; LL, lower limb; TSI, tissue saturation index; τ, mV̇O2 recovery time constant; k, mV̇O2 re-
covery rate constant (k = (1/τ).60, min-1); CON, control. 
 
Figure 3. Median and interquartile ranges of medial forearm (upper limb, UL) and medial gas-
trocnemius (lower limb, LL) skeletal muscle V̇O2 recovery rate constant in COPD and control 
(CON) group. Dotted line indicates the group mean. k, mV̇O2 recovery rate constant; UL, upper 
limb; LL, lower limb; COPD, chronic obstructive pulmonary disease; CON, control; *, main effect 
of condition (COPD vs CON), P≤0.001. 
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 Table 1. Participant characteristics. 
 
  
COPD  CON P value 
n. 
 
19 
 
19 - 
Age (years) 
 
64 (±9) 
 
62 (±7) 0.44 
Weight (kg) 
 
72 (±17) 
 
78 (±17) 0.23 
Height (cm) 
 
171 (±10) 
 
170 (±10) 0.76 
BMI (kg/m2) 
 
24 (±4) 
 
27 (±4) 0.06 
Sex (M / F) 
 
14 / 5 
 
14 / 5 - 
Race (AA / NHW) 
 
5 / 14 
 
11 / 8 - 
FVC (L) 
 
3.1 (±0.9) 
 
3.7 (±0.8) 0.02 
FEV1 (L) 
 
1.6 (±0.8) 
 
2.8 (±0.6) 0.0001 
FEV1/FVC (%) 
 
47.3 (±15.2) 
 
75.6 (±4.0) 0.0001 
FEV1 %pred 
 
44.1 (±18.7) 
 
97.1 (±12.1) 0.0001 
Resting SpO2 (%) 
 
97 (±1.6)* 
 
97 (±1.3) 0.39 
Smoking history 
(ATS pack.years)  37 (±15)  38 (±19) 0.41 
GOLD stage (2 / 3 /4) 
 
7 / 6 / 6 
 
0 / 0 / 0 - 
Data are mean (± SD). COPD, chronic obstructive pulmonary disease 
patients. CON, controls. BMI, body mass index. M, male. F, female. AA, 
African American. NHW, Non-Hispanic White. FVC, forced vital capacity. 
FEV1, forced expiratory volume in 1 second. SpO2, arterial oxygen saturation 
from finger pulse oximetry. GOLD, Global Initiative for Chronic Obstructive 
Lung Disease.  
* Four COPD patients required nasal cannula O2 during the visit (at 2 L.min-
1) 
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Table 2. Symptoms and health-related quality of life questionnaire scores (A); Physical 
activity triaxial accelerometry monitoring (B). 
A  COPD 
 
CON P value 
COPD Assessment test (CAT) 
 
16 [6-29] 5 [0-18]  0.001 
Modified MRC Dyspnea Scale (mMRC) 
 
2 [0-4] 0 [0-1]  0.01 
St. George's Respiratory Questionnaire (SGRQ) score: 
Total 
 
36 [11-73] 6 [0-48] 
 
0.0002 
Active 
 
48 [12-100] 12 [0-66] 
 
0.0001 
Symptom 
 
30 [0-56] 7 [0-48] 
 
0.005 
Impacts 
 
31 [0-80] 0 [0-39] 
 
0.001 
Short Form Health Survey (SF-36) total score:  
  
Mental Component Summary 
 
46 [35-63] 51 [33-61] 
 
0.405 
Physical Component Summary 
 
39 [22-55] 55 [34-62] 
 
0.0006 
Physical Functioning Scale 
 
38 [19-55] 53 [28-57] 
 
0.001 
Role-Physical Scale 
 
37 [18-57] 57 [35-57] 
 
0.0002 
Body Pain Scale 
 
55 [37-62] 62 [33-61] 
 
0.64 
General Health Scale 39 [26-53] 46 [38-63] 0.009 
B  COPD 
 
CON P value 
Days of monitoring (n) 
 
6.2 (±0.4) 6.0 (±0.0) 
 
1.000 
Daytime VMU/min (count) 
Steps per day (n) 
 300 (±170)  
4738 (±3194) 
481 (±113) 
6372 (±2107) 
 0.042 
0.286 
A. Questionnaire scores are median [range min-max]. B. Data are mean (±SD). COPD, 
chronic obstructive pulmonary disease. CON, controls. VMU = vector magnitude units. 
GOLD, Global Initiative for Chronic Obstructive Lung Disease. Questionnaire SF-36: The 
Mental and Physical Component Summary are aggregate scores. 
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Table 3. Skeletal muscle characteristics. 
    
 
 
  
 
COPD  CON P value 
Upper Limb (R/L)  
 
3 / 16 
 
4 / 15  
Saturation (TSI) (%) 
 
66 (±6) 
 
67 (±7) 0.22 
ATT (mm) 3.5 (±1.1) 
 
4.1 (±2.2) 0.28 
k (min-1)   1.01 (±0.17)   1.29 (±0.49) 0.03 
Lower Limb (R/L) 
 
18 / 1 
 
16 / 3  
Saturation (TSI) (%) 
 
67 (±4) 
 
68 (±5) 0.23 
ATT (mm) 4.5 (±2.8) 
 
4.8 (±2.1) 0.77 
k (min-1) 
 
1.05 (±0.24) 
 
1.54 (±0.60) 0.002 
Data are mean (±SD). COPD, chronic obstructive pulmonary disease patients. 
CON, controls. R, right. L, left. TSI, tissue saturation index. ATT, adipose tissue 
thickness. k, rate constant of muscle oxygen consumption recovery kinetics. 
GOLD, Global Initiative for Chronic Obstructive Lung Disease.  
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